UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 6, 2017

 

ARCH THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Nevada   000-54986   46-0524102
(State or other jurisdiction   (Commission   (I.R.S. Employer
of incorporation)   File Number)   Identification No.)

 

235 Walnut Street, Suite 6  
Framingham, Massachusetts 01702
(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (617) 431-2313

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

     

 

Item 7.01 Regulation FD Disclosure.

On June 6, 2017, Arch Therapeutics, Inc. (the “ Company ”) issued a press release in connection with the corporate update that it presented at the LD Micro Invitational at the Luxe Sunset Boulevard Hotel in Los Angeles, California. The text of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

Item 8.01 Other Events.

The disclosure under Item 7.01 (Regulation FD Disclosure) is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibit

 (d) Exhibits

Exhibit   Description
99.1 Press Release issued by Arch Therapeutics, Inc. on June 6, 2017


     

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

  ARCH THERAPEUTICS, INC.  
     
Dated: June 6, 2017 By: /s/ Terrence W. Norchi, M.D.  
  Name:   Terrence W. Norchi, M.D.  
  Title: President, Chief Executive Officer  
       

 

 

     

 

 

Exhibit List

Exhibit   Description
99.1 Press Release issued by Arch Therapeutics, Inc. on June 6, 2017

 

 

     

 

Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Arch Therapeutics (QB) Charts.
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Arch Therapeutics (QB) Charts.